The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.
Abstract
PURPOSE: The Berlin-Frankfurt-Munster (BFM) 76/79 trial of acute lymphoblastic leukemia (ALL) in children produced impressive disease-free survival (DFS) rates with a protocol that began with 8 weeks of intensive therapy, followed by 8 weeks of maintenance therapy, and then another 6 weeks of intensive treatment. The current study was conducted to determine the relative contributions of each of these periods of intense therapy on the DFS rates of ALL patients with intermediate presenting features. In addition, due to concerns regarding the toxicity of CNS irradiation, we compared cranial irradiation (CXRT) with intrathecal methotrexate (IT MTX) administered during induction and consolidation to IT MTX during all phases of the treatment program. PATIENTS AND METHODS: Between May 1983 and April 1989, more than 1,600 children with ALL and intermediate presenting features, as defined by the Childrens Cancer Group (CCG), were entered into a randomized trial that tested four systemic therapy regimens and two CNS programs. RESULTS: The results with a median follow-up of 57 months show that systemic regimens with a delayed intensification (Delint) phase of therapy had a 5-year event-free survival (EFS) rate of 73% compared with the control regimen EFS rate of 61% (p = .006). For children less than 10 years of age, standard three-drug induction and Delint produced a 77% 5-year EFS. IT MTX during all phases of therapy provided CNS protection comparable to the CXRT regimen in children less than 10 years of age. Children 10 years of age or older appear to have a better EFS rate with intensive induction, Delint, and CXRT. CONCLUSION: Delint improves the EFS rate of children with ALL and intermediate presenting features. Maintenance IT MTX can be safely substituted for CXRT for presymptomatic CNS therapy in children with intermediate-risk characteristics less than 10 years of age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freiman, J. A., Chalmers, T. C., Smith, H., & Kuebler, R. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197809282991304 · Cited by 1,628
Cited by
Smith, M., Arthur, D., Camitta, B., Carroll, A. J., Crist, W., Gaynon, P., Gelber, R., Heerema, N., Korn, E. L., Link, M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.18 · Cited by 901
Self-citationPui, C.-H., & Evans, W. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390907 · Cited by 832
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Kantarjian, H. M., O’Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff, M., Koller, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.547 · Cited by 796
Reiter, A., Schrappe, M., Ludwig, W., Hiddemann, W., Sauter, S., Henze, G., Zimmermann, M., Lampert, F., Havers, W., & Niethammer, D. (1994) · Blood · doi:10.1182/blood.v84.9.3122.3122 · Cited by 621
Boissel, N., Auclerc, M.-F., Lhéritier, V., Perel, Y., Thomas, X., Leblanc, T., Rousselot, P., Cayuela, J.-M., Gabert, J., Fegueux, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.053 · Cited by 608
Metadata
- Authors
- Tubergen, D. G., Gilchrist, G. S., O'Brien, R. T., Coccia, P. F., Sather, H. N., Waskerwitz, M. J., & Hammond, G. D.
- Venue
- Journal of Clinical Oncology
- Published
- 1993-03
- Volume
- 11
- Issue
- 3
- Pages
- 527-537
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1949967960
- Cited by
- 221
- References
- 1
- FWCI
- 17.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. https://app.cochat.ai/papers/10.1200/jco.1993.11.3.527
- The paper
- Tubergen, D. G., Gilchrist, G. S., O'Brien, R. T., Coccia, P. F., Sather, H. N., Waskerwitz, M. J., & Hammond, G. D. (1993). Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1993.11.3.527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.